Clinical Trials
5 trialsNCT04940052 2026-06-04
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
Phase 3 Active not recruiting
NCT02224781 2026-05-29
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06475989 2026-05-15
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed